“High Costs With Small Benefits” New Alzheimer’s Drug Blocked For Use On NHS
The NHS spending watchdog has recommended that a drug shown to slow the progression of Alzheimer’s disease should not be rolled out on the health service, despite the UK medicines regulator saying it is safe and effective for use.
The National Institute for Health and Care Excellence (Nice) said the benefits of lecanemab are “just too small to justify the significant cost to the NHS”.
Talk’s Mike Graham speaks to director of Medicines Evaluation at Nice, Helen Knight, who explains why the drug was rejected.
#nhs #healthcare #health
Credit to : TalkTV
